{
  "docId": "019de074-ad31-7288-aa0c-b4a964d6a9af",
  "docSlug": "31aafddb38d645745d1c40d83b8ae135",
  "documentTitle": "ATAI | Investor Presentation Deck | 30 slides",
  "authorId": "atai",
  "authorName": "atai",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 30,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "The slide uses a numbered list to highlight key safety findings alongside a detailed data table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ad31-7288-aa0c-b4a964d6a9af/17",
  "deckHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af",
  "deckJsonHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af.json",
  "deckAnchorHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: TEAE = Treatment-emergent Adverse Event, SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. n = number of subjects reporting at least one TEAE in that category, % = proportion of cohort total. Defined as an adverse event that began after the start of trial medication treatment. Non-exhaustive. Other recorded TEAEs included Upper respiratory tract infection (3%), Rash erythematous (3%), Dysmenorrhoea (3%), Catheter site pain (3%). Of the 565 patients given XANAX in Ph.3 placebo-controlled trials for anxiety disorders, 41% reported drowsiness versus 22% of those administered placebo (as reported in XANAX FDA label).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a68ea095-703e-4f55-bed7-69d8406cc166",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Given every 12 hours for 7 days, GRX-917 was well-tolerated with no dose-limiting toxicities identified up to the highest dose of 300mg. 2. There were no serious adverse events reported nor dose-related discontinuations due to adverse events. 3. Adverse events in both single- and multiple-ascending dose (SAD and MAD) regimens were comparable to placebo-treated subjects. 4. No significant evidence of sedation or other benzodiazepine-like side effects at any doses tested.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d78f27c4-3099-4f4d-8692-d5da468b6ecd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.42,
        "y": 0.23
      },
      "kind": "table",
      "text": "GRX-917 Phase 1 MAD study safety data table including TEAEs and most common adverse events.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f2de987-da8f-4d3f-bc2e-db502661f047",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "GRX-917 Phase 1 data: No severe or serious adverse events, with minimal sedation or dizziness, confirms favourable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "955c6729-5ee7-4eb0-9149-94ead9ebc69b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "ac5e080c-b74d-4115-a83a-25ce54f0c50b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 9-24 present traction data for various programs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8a640552-7d64-4f46-af4c-8041a39da251",
      "evidence": "The deck presents a clear and compelling vision for ATAI's mission and solution",
      "position": 1,
      "objective": "Present a compelling vision for ATAI's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}